Miller DH, Barkhof F, Frank JA, et al: Measurement of atrophy in multiple sclerosis: Pathological basis, methodological aspects and clinical relevance. Brain 125:1676, 2002.
Miller DH, Khan OA, Sheremata WA, et al: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15, 2003.
Moulin D, Paty DW, Ebers GC: The predictive value of CSF electrophoresis in “possible” multiple sclerosis. Brain 106:809, 1983.
Munger KL, Levin LI, Hollis BW, et al: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832, 2006.
Narisco P, Galgani S, Del Grosso B, et al: Acute disseminated encephalomyelitis as manifestation of primary HIV infection. Neurology 57:1493, 2001.
National Center for Health Statistics, Collins JG: Types of Injuries and Impairments due to Injuries. United States Vital Statistics. Series 10, no 159, DHHS, no (PHS) 871587. Washington, DC, U.S. Public Health Service, 1986.
O’Connor P, Wolinsky JS, Confavreux C, et al; TEMSO Trial Group: Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293, 2011.
Optic Neuritis Study Group: The five-year risk of MS after optic neuritis. Neurology 49:1404, 1997.
Ormerod IEC, McDonald WI, DuBoulay GH, et al: Disseminated lesions at presentation in patients with optic neuritis. J Neurol Neurosurg Psychiatry 49:124, 1986.
Osterman PO, Westerberg CE: Paroxysmal attacks in multiple sclerosis. Brain 98:189, 1975.
Padovan CS, Bise K, Hahn J, et al: Angiitis of the central nervous system after allogenic bone marrow transplantation? Stroke 30:1651, 1999.
Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: A review. Multiple Sclerosis 21:845, 2015.
Percy AK, Nobrega FT, Okazaki H: Multiple sclerosis in Rochester, Minnesota: A 60-year appraisal. Arch Neurol 25:105, 1971.
Pittock SJ, Lennon VA, de Seze J, et al: Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65:78, 2008.
Pittock SJ, Mayr WT, McClelland RL, et al: Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 62:601, 2004.
Pittock SJ, Weinshenker BG, Lucchinetti CF, et al: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63:964, 2006.
Polman CH, O’Connor PW, Havardova E, et al: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899, 2006.